English

CS MEDICA A/S: Minutes of Extraordinary General Meeting

Report this content

CS MEDICA Approves Key Proposals at Extraordinary General Meeting

CS MEDICA (”CS MEDICA” or “The Company”) is pleased to announce the successful approval of several key proposals at its Extraordinary General Meeting (EGM) held on July 31, 2024.  The approved resolutions are as follows:

  1. Election of Chairman of the Meeting
    • Flemming Heegard was elected as the chairman of the meeting.
  2. Capital Increase for Remuneration of IR Agreement
    • The shareholders approved a capital increase of 317,000 shares at DKK 3.00 per share, without pre-emption rights for existing shareholders.
    • The shares will be subscribed by Börsjakten AB or its related companies/persons, including its investor network.
    • These shares will be used to offset remuneration for an Investor Relations (IR) Agreement with Börsjakten AB, amounting to SEK 1,450,000.
    • The IR Agreement is set to run until July 11, 2025.
  3. Cash Capital Increase
    • The shareholders approved a cash capital increase of 499,200 shares at DKK 3.00 per share, without pre-emption rights for existing shareholders.
    • The shares will be subscribed by Börsjakten AB or its related companies/persons, including its investor network.
  4. Issuance of New Shares for IR-Related Activities
    • The shareholders approved the issuance of 3,000,000 new shares to CS MEDICA, with a nominal value of DKK 0.065 per share.
    • These shares will be used to secure payment for Investor Relations (IR) related activities.
    • The Company plans to engage various firms to enhance investor communication and engagement.
    • Remuneration for these IR-related services will be offset through the issuance of the proposed 3,000,000 shares, with the number of shares calculated monthly based on the invoices from the service providers, using the share price at the end of each month.

The total number of votes as of the date of this Statement is 12,322,635, of which 71.8%, equal to 8,842,160 votes, were represented at the EGM. The resolutions were approved unanimously by all shareholders represented at the EGM.
 

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
 

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes. 

Tags:

EGM CSMEDICA minutes

Subscribe

Documents & Links